Literature DB >> 26810473

Treatment and survival of supratentorial and posterior fossa ependymomas in adults.

Miriam Nuño1, Jeffrey J Yu2, Kunal Varshneya2, Julia Alexander2, Debraj Mukherjee2, Keith L Black2, Chirag G Patil2.   

Abstract

Ependymoma is a rare primary brain or spinal cord tumor that arises from the ependyma, a tissue of the central nervous system. This study analyzed a large cohort of adult supratentorial and posterior fossa ependymoma tumors in order to elucidate factors associated with overall survival. We utilized the USA National Cancer Database to study adult World Health Organization grade II/III supratentorial and posterior fossa ependymoma patients treated between 1998 and 2011. Overall survival was estimated by the Kaplan-Meier method and factors associated with survival were determined using a multivariate Cox proportional hazards model. Among 1318 patients, 1055 (80.0%) had grade II and 263 (20.0%) anaplastic tumors located in the posterior fossa (64.3%) and supratentorial region (35.7%). Overall average age was 44.3years, 48.0% of patients were female, 86.5% were Caucasian, and 36.8% underwent near/gross total surgical resection. Radiotherapy was given to 662 patients (50.8%) and 75 (5.9%) received chemotherapy. Older age at diagnosis (hazard ratio [HR] 1.51, p<0.0001), high tumor grade (HR 1.82, p=0.005), and large tumor size (HR 1.66, p=0.008) were associated with poor survival. Females compared to males (HR 0.67, p=0.03) and patients with posterior fossa tumors versus supratentorial (HR 0.64, p=0.04) had a survival advantage. Our study showed that older patients, with supratentorial tumors, and high histological grade had an increased risk of mortality. A survival benefit was captured in females and patients with posterior fossa tumors. Adjuvant radiotherapy and chemotherapy did not confer a survival benefit among all patients, even after stratification by tumor grade or anatomical location.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Ependymomas; Overall survival; Posterior fossa; Radiotherapy; Supratentorial

Mesh:

Year:  2016        PMID: 26810473     DOI: 10.1016/j.jocn.2015.11.014

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  8 in total

Review 1.  EANO guidelines for the diagnosis and treatment of ependymal tumors.

Authors:  Roberta Rudà; Guido Reifenberger; Didier Frappaz; Stefan M Pfister; Anne Laprie; Thomas Santarius; Patrick Roth; Joerg Christian Tonn; Riccardo Soffietti; Michael Weller; Elizabeth Cohen-Jonathan Moyal
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

2.  The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.

Authors:  Kristian W Pajtler; Stephen C Mack; Vijay Ramaswamy; Christian A Smith; Hendrik Witt; Amy Smith; Jordan R Hansford; Katja von Hoff; Karen D Wright; Eugene Hwang; Didier Frappaz; Yonehiro Kanemura; Maura Massimino; Cécile Faure-Conter; Piergiorgio Modena; Uri Tabori; Katherine E Warren; Eric C Holland; Koichi Ichimura; Felice Giangaspero; David Castel; Andreas von Deimling; Marcel Kool; Peter B Dirks; Richard G Grundy; Nicholas K Foreman; Amar Gajjar; Andrey Korshunov; Jonathan Finlay; Richard J Gilbertson; David W Ellison; Kenneth D Aldape; Thomas E Merchant; Eric Bouffet; Stefan M Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2016-11-17       Impact factor: 17.088

Review 3.  An Overview of Intracranial Ependymomas in Adults.

Authors:  Giuseppe Lombardi; Alessandro Della Puppa; Marco Pizzi; Giulia Cerretti; Camilla Bonaudo; Marina Paola Gardiman; Angelo Dipasquale; Fabiana Gregucci; Alice Esposito; Debora De Bartolo; Vittorina Zagonel; Matteo Simonelli; Alba Fiorentino; Francois Ducray
Journal:  Cancers (Basel)       Date:  2021-12-05       Impact factor: 6.639

4.  Do We Need Radiotherapy in Grade II Ependymoma?

Authors:  Aleksandra Napieralska; Wojciech Majewski; Leszek Miszczyk
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

5.  Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000-2016.

Authors:  Rebecca L Achey; Sierra Vo; Gino Cioffi; Haley Gittleman; Julia Schroer; Vishesh Khanna; Robin Buerki; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neurooncol Pract       Date:  2020-05-09

6.  The effect of adjuvant radiotherapy on overall survival in adults with intracranial ependymoma.

Authors:  Roshan S Prabhu; Christopher D Corso; Matthew C Ward; John H Heinzerling; Reshika Dhakal; Zachary S Buchwald; Kirtesh R Patel; Anthony L Asher; Ashley L Sumrall; Stuart H Burri
Journal:  Neurooncol Pract       Date:  2019-12-19

7.  Personalizing age-specific survival prediction and risk stratification in intracranial grade II/III ependymoma.

Authors:  Xiangyang Deng; Xiaojia Zhang; Liang Yang; Xiangqi Lu; Junhao Fang; Lisheng Yu; Dandong Li; Hansong Sheng; Bo Yin; Nu Zhang; Jian Lin
Journal:  Cancer Med       Date:  2019-12-03       Impact factor: 4.452

8.  Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.

Authors:  A Kaywan Aftahy; Melanie Barz; Philipp Krauss; Friederike Liesche; Benedikt Wiestler; Stephanie E Combs; Christoph Straube; Bernhard Meyer; Jens Gempt
Journal:  BMC Cancer       Date:  2020-11-03       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.